Attached files
file | filename |
---|---|
EX-21 - EXHIBIT 21 - Sucampo Pharmaceuticals, Inc. | exh_21.htm |
EX-32.2 - EXHIBIT 32.2 - Sucampo Pharmaceuticals, Inc. | exh_322.htm |
EX-31.1 - EXHIBIT 31.1 - Sucampo Pharmaceuticals, Inc. | exh_311.htm |
EX-32.1 - EXHIBIT 32.1 - Sucampo Pharmaceuticals, Inc. | exh_321.htm |
EX-23.1 - EXHIBIT 23.1 - Sucampo Pharmaceuticals, Inc. | exh_231.htm |
EX-31.2 - EXHIBIT 31.2 - Sucampo Pharmaceuticals, Inc. | exh_312.htm |
EX-10.41 - EXHIBIT 10.41 - Sucampo Pharmaceuticals, Inc. | exh_1041.htm |
EX-10.35 - EXHIBIT 10.35 - Sucampo Pharmaceuticals, Inc. | exh_1035.htm |
EX-10.38 - EXHIBIT 10.38 - Sucampo Pharmaceuticals, Inc. | exh_1038.htm |
EX-10.40 - EXHIBIT 10.40 - Sucampo Pharmaceuticals, Inc. | exh_1040.htm |
10-K - FORM 10-K - Sucampo Pharmaceuticals, Inc. | f10k_030816p.htm |
EX-10.36 - EXHIBIT 10.36 - Sucampo Pharmaceuticals, Inc. | exh_1036.htm |
EX-10.39 - EXHIBIT 10.39 - Sucampo Pharmaceuticals, Inc. | exh_1039.htm |
EX-10.37 - EXHIBIT 10.37 - Sucampo Pharmaceuticals, Inc. | exh_1037.htm |
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-147420) and Form S-3 (333- 201566) of Sucampo Pharmaceuticals, Inc. of our report dated March 10, 2015, except for the change in the composition of reportable segments discussed in Note 4 to the consolidated financial statements, as to which the date is May 6, 2015, relating to the financial statements and financial statement schedule, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Baltimore, Maryland
March 9, 2016